OAC1Oct4 activator |
Sample solution is provided at 25 µL, 10mM.
Quality Control & MSDS
- View current batch:
- Purity = 98.14%
- COA (Certificate Of Analysis)
- HPLC
- NMR (Nuclear Magnetic Resonance)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
OAC1 Dilution Calculator
calculate
OAC1 Molarity Calculator
calculate
Cas No. | 300586-90-7 | SDF | Download SDF |
Chemical Name | N-(1H-pyrrolo[2,3-c]pyridin-5-yl)benzamide | ||
Canonical SMILES | C1=CC=C(C=C1)C(=O)NC2=NC=C3C(=C2)C=CN3 | ||
Formula | C14H11N3O | M.Wt | 237.26 |
Solubility | ≥9.9mg/mL in DMSO | Storage | Store at -20°C |
Physical Appearance | A solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. |
OAC1 is an activator of Oct4 [1].
Octamer-binding transcription factor 4 (Oct4) is a regulator of embryonic stem cell (ESC) pluripotency and the reprogramming process. High expression of Oct4 results in differentiation of ESCs along the mesodermal and primitive endodermal lineages. However, low expression of Oct4 leads to differentiation of ESCs into trophectodermal cells [1].
OAC1 is an Oct4 activator. In luciferase reporter assays, OAC1 activated both human Oct4 and Nanog promoter-driven luciferase reporter genes. In mouse embryonic fibroblasts (MEFs) with the 4F reprogramming quartet Oct4, Klf4, Sox2, and c-Myc, OAC1 enhanced reprogramming efficiency and increased the number of colonies with ESC-like morphology by twofold or more. Also, OAC1 increased induced pluripotent stem cells (iPSC)-like colonies. OAC1 had no effects on the Wnt signaling and p53-p21 expression. In MEFs, OAC1 activated the expression of endogenous Oct4 and Nanog. Also, OAC1 increased the expression of Sox2 and Tet1 [1].
Reference:[1]. Li W, Tian E, Chen ZX, et al. Identification of Oct4-activating compounds that enhance reprogramming efficiency. Proc Natl Acad Sci U S A, 2012, 109(51): 20853-20858.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
《血管紧张素转换酶抑制剂在心血管病中应用的中国专家共识》.PDF(242.69k)
1、测定酶比活力:底物需要过量么?测定时间多长?是否可以加入过量的底物,然后测定3min吸光度的增加值,从吸光度的变化值计算比活力。
2、在酶抑制剂筛选的过程中,是否需要保证底物过量?还是要水浴一定时间让反应完全?我看到文献说用终浓度为0.1μmol/mL的底物,终浓度为45U/ml的酶,我想问,假设总体积为1ml,那么终浓度为45U/ml的酶岂不是每分钟能转化4.8μmol的底物?那么0.1μmol/mL的底物不就几秒钟就反应完了?那么怎么测定初速度?
1.对于抑制剂筛选工作(求ic50)是不是体系内酶与底物的量(底物应该是过量的)对实验结果影响不大。
2.如果要求算Km值,是不是需要知道反应产物的绝对量。反应时间文献上都是5分钟,反应速度就用反应产物量除以反应时间即可。
3.酶是进口分装的,规格5U,一次用不完,用PBS稀释后如何保存
谢谢
2、可逆抑制剂:包括
a、竞争性抑制剂,抑制剂与底物竞争性结合酶反应中心,使Km增大,而Vmax不变 b、非竞争性抑制剂,酶与抑制剂结合后还能与底物结合,但活性降低,使Vmax减小,而Km不变
c、反竞争性抑制剂,酶只能与底物结合后才能与抑制剂结合,Vmax与Km都减小
可逆抑制剂可用透析等方法除去,使酶恢复作用
暂无品牌问答